Evidence map›Paper›PMID 19587710›Full record

ReviewGene therapy2009

Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches.

K H Link, R R Breaker

Abstract readReview
In one paragraph

Review in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Riboswitches.Current biology : CB · 2023
    Article
  5. Discovering riboswitches: the past and the future.Trends in biochemical sciences · 2023
    Review
  6. Article
  7. Article
  8. The case of the missing allosteric ribozymes.Nature chemical biology · 2021
    Review
  9. Riboswitches and Translation Control.Cold Spring Harbor perspectives in biology · 2018
    Review
  10. Article
  11. Synthetic Botany.Cold Spring Harbor perspectives in biology · 2017
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Artificial riboswitches for gene expression and replication control of DNA and RNA viruses.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

K H LinkHoward Hughes Medical Institute, Yale University, New Haven, CT, USA.
R R Breaker

Funding

Natural mRNA Genetic Switches that Bind MetabolitesR01GM068819 · NIGMS · YALE UNIVERSITY · PI BREAKER, RONALD R · 2003 to 2006
$1.3M
Howard Hughes Medical InstituteNIGMS NIH HHS R01 GM068819
6 · The paper itself

Abstract

In the last two decades, remarkable advances have been made in the development of technologies used to engineer new aptamers and ribozymes. This has encouraged interest among researchers who seek to create new types of gene-control systems that can be made to respond specifically to small-molecule signals. Validation of the fact that RNA molecules can exhibit the characteristics needed to serve as precision genetic switches has come from the discovery of numerous classes of natural ligand-sensing RNAs called riboswitches. Although a great deal of progress has been made toward engineering useful designer riboswitches, considerable advances are needed before the performance characteristics of these RNAs match those of protein systems that have been co-opted to regulate gene expression. In this review, we will evaluate the potential for engineered RNAs to regulate gene expression and lay out possible paths to designer riboswitches based on currently available technologies. Furthermore, we will discuss some technical advances that would empower RNA engineers who seek to make routine the production of designer riboswitches that can function in eukaryotes.

Indexed as

Allosteric RegulationAptamers, NucleotideGene Expression RegulationGenetic EngineeringHumansLigandsRNA, CatalyticAptamers, NucleotideLigandsRNA, Catalytic

Identifiers

PMID19587710
PMCPMC5325117

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.